Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

With increasing knowledge on molecular tumour information, precision oncology has
revolutionised the medical field over the past years. Liquid biopsy entails the analysis of …

To identify disease-relevant T cell receptors (TCRs) with shared antigen specificity, we
analyzed 778,938 TCRβ chain sequences from 178 non-small cell lung cancer patients …